FISHER & PAYKEL HEALTHCARE CORPORATION LIMITED (FPH)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

FPH

FPH - FISHER & PAYKEL HEALTHCARE CORPORATION LIMITED

FNArena Sector : Medical Equipment & Devices
Year End: March
GICS Industry Group : Health Care Equipment & Services
Debt/EBITDA: 0.23
Index: ASX100 | ASX200 | ASX300 | ALL-ORDS

Fisher & Paykel Healthcare is a designer and manufacturer of systems used in respiratory care and treatment of sleep disorders. It was separated from Fisher & Paykel and listed on the ASX and NZX in 2001. A brief Nasdaq listing was terminated in 2003. Only 1% of its revenues stems from New Zealand.

LAST PRICE CHANGE +/- CHANGE % VOLUME

$33.09

05 Dec
2025

0.050

OPEN

$32.85

0.15%

HIGH

$33.09

365,019

LOW

$32.67

TARGET
$37.00 11.8% upside
OTHER COMPANIES IN THE SAME SECTOR
4DX . AT1 . AYA . BB1 . BRN . CAT . CBL . CGS . CMP . COH . CSX . CU6 . CVB . CYC . EBR . EMV . EYE . IME . IMR . IPD . LDX . MX1 . NAN . ONE . PCK . PEB . PGC . PME . RMD . SOM . TRJ . UBI .
FNARENA'S MARKET CONSENSUS FORECASTS
FPH: 1
Title FY26
Forecast		 FY27
Forecast
EPS (cps) 69.1 xxx
DPS (cps) 45.4 xxx
EPS Growth N/A xxx
DPS Growth N/A xxx
PE Ratio 47.9 xxx
Dividend Yield 1.4% xxx
Div Pay Ratio(%) 65.7% xxx
This company reports in NZD.
All estimates have been converted into AUD by FNArena at present FX values.

Dividend yield today if purchased 3 years ago: 1.68%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 1.12

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages

Last ex-div: 05/12 - (franking ex-di

HISTORICAL DATA ARE ALL IN AUD
Copyright © 2025 FactSet UK Limited. All rights reserved
Title 202020212022202320242025
EPS Basic xxxxxxxxxxxxxxx58.6
DPS All xxxxxxxxxxxxxxx45.5
Sales/Revenue xxxxxxxxxxxxxxx1,842.0 M
Book Value Per Share xxxxxxxxxxxxxxx293.2
Net Operating Cash Flow xxxxxxxxxxxxxxx499.4 M
Net Profit Margin xxxxxxxxxxxxxxx18.64 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 202020212022202320242025
Return on Capital Employed xxxxxxxxxxxxxxx20.62 %
Return on Invested Capital xxxxxxxxxxxxxxx19.75 %
Return on Assets xxxxxxxxxxxxxxx15.57 %
Return on Equity xxxxxxxxxxxxxxx20.62 %
Return on Total Capital xxxxxxxxxxxxxxx25.59 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx254.1 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 202020212022202320242025
Short-Term Debt xxxxxxxxxxxxxxx79 M
Long Term Debt xxxxxxxxxxxxxxx61 M
Total Debt xxxxxxxxxxxxxxx139 M
Goodwill - Gross xxxxxxxxxxxxxxx-
Cash & Equivalents - Generic xxxxxxxxxxxxxxx240 M
Price To Book Value xxxxxxxxxxxxxxx10.40

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 202020212022202320242025
Capex xxxxxxxxxxxxxxx93.8 M
Capex % of Sales xxxxxxxxxxxxxxx5.09 %
Cost of Goods Sold xxxxxxxxxxxxxxx683 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx693 M
Research & Development xxxxxxxxxxxxxxx207 M
Investments - Total xxxxxxxxxxxxxxx35 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

0.5

No. Of Recommendations

4
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Macquarie

xx/xx/xxxx

1

xxxxxxxxxx

-

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Citi

xx/xx/xxxx

3

xxxxxxx

-

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

UBS

27/11/2025

3

Neutral

-

-

Fisher & Paykel Healthcare reported a 1H26 result which was 7% better than UBS' expectations due to reduced capex and a tailwind from a stronger NZD. On a constant currency basis, 1H26 EBIT lifted 26% and beat the analyst's forecast by 4%.

The analyst lifts EPS estimates by 3% for FY26 and 2% for both FY27 and FY28 due to lower revenue in hospital (flu season) and homecare (lower mask share), offset by improved cost management. A US tariff impact of -NZ$12m is included.

Current stock price levels factor in the anticipated EPS growth rate (CAGR) of 17% from FY26, underpinned by high-flow therapy adoption, the analyst states, and robust obstructive sleep apnea new patient starts, as well as margin expansion and NZD weakness.

The target price is raised to NZ$39.30 from NZ$37.00 with no change in Neutral rating.

FORECAST
UBS forecasts a full year FY26 dividend of 50.66 cents and EPS of 69.66 cents.
UBS forecasts a full year FY27 dividend of 58.81 cents and EPS of 82.33 cents.

Morgan Stanley

xx/xx/xxxx

1

xxxxxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial
Access Stockbroker Research History >
EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

2

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Canaccord Genuity

xx/xx/xxxx

1

xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Jarden

26/11/2025

3

Neutral

-

-

Fisher & Paykel Healthcare delivered a strong 1H26 result, assesses Jarden, with revenue and mix broadly in line but earnings (EBIT) around 5% ahead on better margins and currency hedging.

The broker highlights Hospital as the standout, driven by strong hardware demand, double-digit invasive ventilation (IV) consumables growth and continued expansion in New Applications.

Homecare performed as the analysts expected, with cycling effects and some device pull-forward tempering growth.

Guidance for profit was raised by NZ$20m, reflecting consumables outperformance, margin gains and opex leverage, explain the analysts, with flu season dynamics determining the range outcome.

Neutral. Target edges up to NZ$39.30 from NZ$38.90.

FORECAST
Jarden forecasts a full year FY26 dividend of 44.33 cents and EPS of 71.11 cents.
Jarden forecasts a full year FY27 dividend of 50.66 cents and EPS of 81.79 cents.
Access Extra Coverage Research History >

FPH STOCK CHART

FNArena News on FPH

Latest Medical Equipment & Devices News

1
Shortages Chip Away At ResMed’s Big Break

Mar 30 2022 - Australia
2
Opportunity for Fisher & Paykel Healthcare

Mar 25 2022 - Australia
3
Distribution Anxiety For Nanosonics

Feb 10 2022 - Australia
4
Brokers Awake To ResMed’s Potential

Jan 31 2022 - Australia
5
Covid Benefits F&P Healthcare, For Now

Dec 06 2021 - Australia
6
Will Shortages Limit Upside For ResMed?

Nov 01 2021 - Australia
7
Nanosonics Unveils Its New Product

Aug 26 2021 - Australia
8
Pro Medicus: Opportunity Awaits

Aug 24 2021 - Technicals
9
Breakout For Cochlear

Aug 10 2021 - Technicals
10
Will ResMed’s Market Share Gains Last?

Aug 09 2021 - Australia